Ligand Pharmaceuticals Incorporated
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $1.01B | $115.1M | $174.9M | $139.4M | $67.7M | $48.0M | $72.3M | $63.6M |
| Accounts Receivable | $67.0M | $53.4M | $59.6M | $57.6M | $41.3M | $38.5M | $38.4M | $34.3M |
| Inventory | $10.3M | $13.3M | $9.1M | $11.9M | $15.5M | $14.6M | $14.1M | $16.7M |
| Total Current Assets | $1.46B | $865.4M | $832.3M | $753.9M | $352.9M | $309.3M | $331.6M | $309.4M |
| Property, Plant & Equipment | $3.4M | $3.4M | $3.6M | $3.5M | $3.6M | $3.6M | $15.1M | $15.1M |
| Goodwill | $101.5M | $101.5M | $101.5M | $101.5M | $101.5M | $101.5M | $105.3M | $105.3M |
| Intangible Assets (Excl. Goodwill) | $209.2M | $217.3M | $225.4M | $233.5M | $250.1M | $258.4M | $266.6M | $274.9M |
| Total Assets | $2.19B | $1.53B | $1.56B | $1.48B | $948.6M | $905.4M | $941.8M | $954.9M |
| Liabilities | ||||||||
| Accounts Payable | $9.4M | $5.3M | $3.2M | $3.7M | $8.6M | $5.4M | $5.2M | $4.7M |
| Total Current Liabilities | $46.7M | $40.7M | $37.4M | $30.5M | $64.7M | $58.7M | $37.1M | $24.8M |
| Long-Term Debt | $1.13B | — | — | — | — | — | — | — |
| Total Liabilities | $1.22B | $534.8M | $543.4M | $526.6M | $120.1M | $109.9M | $111.3M | $113.7M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $583.3M | $594.7M | $608.1M | $578.2M | $461.4M | $456.5M | $499.0M | $530.1M |
| Total Stockholders' Equity | $967.5M | $997.3M | $1.02B | $950.2M | $827.3M | $795.6M | $830.4M | $841.2M |